EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study

Michele Malagola, Domenica Matranga, Luca Castagna, Daniele Avenoso, Vera Radici, Mirko Farina, Marco Galli, Eugenia Accorsi Buttini, Caterina Alati, Simona Bassi, Alessandra Biffi, Carlo Borghero und 30 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-05 · 26 (5) · 328-339.e2

DOI: 10.1016/j.clml.2026.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-05. Verfasst von Michele Malagola und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Adult Bone Marrow Transplant Unit, Program of Cellular Thera…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse is the most frequent cause of allogeneic stem cell transplantation (allo-SCT) failure. The utility of post-relapse therapy is controversial due to the high incidence of toxicity and the low efficacy. METHODS: This sub-analysis of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) AML/MDS relapse study focuses on 647 AML/MDS relapsing after allo-SCT performed between 2015 and 2021. Following the relapse, these patients were treated with either hypomethylating agents (HMAs)-based therapy (n = 308) or other treatments (n = 339), including intensive chemotherapy, FLT3-inhibitors, and second allo-SCT. RESULTS: HMAs-based therapies were more frequently used in older patients, transplanted not in CR following a reduced-intensity conditioning regimen. The overall response rate (ORR) with or without HMA-based salvage treatment was 33% and 40%, respectively (P = .006). The complete remission (CR) rate was 23% and 33% in the two groups, respectively (P < .001). The long-term OS and TRM of the two groups were superimposable. Independently from the type of salvage, an advantage in OS was observed when donor lymphocytes infusion (DLI) was included (P < .001). Relapse within 12 months after SCT, low disease burden at relapse, and the CR status at transplant confirmed their independent strong prognostic impact on both HMA and non-HMA-based group (HR 0.05, 0.44, and 0.49 and HR 0.19, 0.32, and 0.53, respectively). CONCLUSIONS: Despite the lower ORR observed with HMA-based therapy, the long-term OS was comparable to that observed with other therapies. The immune control of the disease relapse with DLI is of benefit, independently from the salvage therapy. .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansFemaleMiddle AgedTransplantation, HomologousMaleAdultAgedRegistriesRecurrenceYoung Adult

Stichwörter der Autor:innen

Allo-SCTDonor Lymphocyte InfusionHMAsPre-emptiveVenetoclax

Autor:innen und Institutionen

  • Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Adult Bone Marrow Transplant Unit, Program of Cellular Therapy and Research in Hematology, ASST Spedali Civili di Brescia, Brescia…
  • Department Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
  • BMT Unit, AOR Villa Sofia Cervello, Palermo, Italy.
  • UO Ematologia, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Science, University of Brescia, Brescia, Italy.
  • Hematology and Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
  • UO Ematologia e CTMO, Ospedale Guglielmo da Saliceto, Piacenza, Italy.

Zitieren

APA

Malagola, M., Matranga, D., Castagna, L., Avenoso, D., Radici, V., Farina, M., Galli, M., Buttini, E. A., Alati, C., Bassi, S., Biffi, A., Borghero, C., Busca, A., Nozzoli, C., Carella, A. M., Cavattoni, I. M., Cerretti, R., Chiusolo, P., Cimminiello, M., …, & Martino, M. (2026). Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study. Clinical Lymphoma Myeloma and Leukemia, 26(5), 328-339.e2. https://doi.org/10.1016/j.clml.2026.02.009

Vancouver

Malagola M, Matranga D, Castagna L, Avenoso D, Radici V, Farina M, et al. Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study. Clinical Lymphoma Myeloma and Leukemia. 2026;26(5):328-339.e2. doi:10.1016/j.clml.2026.02.009

BibTeX
@article{Malagola2026,
  author = {Malagola, Michele and Matranga, Domenica and Castagna, Luca and Avenoso, Daniele and Radici, Vera and Farina, Mirko and Galli, Marco and Buttini, Eugenia Accorsi and Alati, Caterina and Bassi, Simona and Biffi, Alessandra and Borghero, Carlo and Busca, Alessandro and Nozzoli, Chiara and Carella, Angelo Michele and Cavattoni, Irene Maria and Cerretti, Raffaella and Chiusolo, Patrizia and Cimminiello, Michele and Cuoghi, Angela and De Gobbi, Marco and Vincenzo, Federico and Galieni, Piero and Iori, Anna Paola and Parma, Matteo and Patriarca, Francesca and Pavone, Vincenzo and Picardi, Alessandra and Piras, Eugenia and Polverelli, Nicola and Prezioso, Lucia and Rambaldi, Benedetta and Saraceni, Francesco and Scalisi, Elvira and Selleri, Carmine and Skert, Cristina and Spina, Alessandro and Tecchio, Cristina and Oldani, Elena and Degrandi, Eliana and Russo, Domenico and Martino, Massimo},
  title = {Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {328--339.e2},
  doi = {10.1016/j.clml.2026.02.009}
}
Kostenlos starten →